Harvard Bioscience, Inc. (HBIO)

Over the past six months, Harvard Bioscience's stock price has been impacted by several events. A reverse stock split on March 6, 2026, led to a decline in the stock price. The announcement of Fourth Quarter and Full-Year 2025 financial results on March 12, 2026, resulted in a stock decline, followed by a subsequent increase over the next 55 days. HBIO participated in the KeyBanc Virtual Healthcare Forum on March 17, 2026, and has scheduled investor conferences. Equity grants were awarded to the CFO and CEO in April 2026. A Schedule 13D filing on March 23, 2026, reported BroadOak's stake in HBIO. Nasdaq granted an extension to regain compliance with the minimum bid price requirement. Overall, the stock has experienced a decline over the past six months.

While direct information on the seasonality of demand for Harvard Bioscience's products and services is not explicitly detailed, the stock price performance exhibits some seasonal patterns. Historically, July has shown the highest probability of positive returns for HBIO stock, while September has the lowest. The company's stock price has also historically reflected the cyclical nature of biotech R&D spending, which could indirectly influence demand for its life science tools and equipment.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications, including research, drug discovery, bio-production, and preclinical testing. The company operates in the Healthcare sector, specifically in the Medical Instruments & Supplies industry, and is categorized under Analytical Laboratory Instrument Manufacturing and Life Sciences Tools & Services. Its product portfolio includes Fluidics, Laboratory Equipment & Supplies, Molecular Analysis, Cell Analysis, and Physiology, organized into Cellular and Molecular Technologies (CMT) and Preclinical families. Major product brands include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Panlab, CMA, KD Scientific, Multi Channel Systems (MCS), Radnoti, and Warner Instruments.

Harvard Bioscience has a global presence with operations in the United States, Europe, and China, selling products through direct sales and distribution partners. While a significant portion of its revenue comes from the United States, it also has a strong presence in Germany, the United Kingdom, and emerging markets in Asia. Its principal manufacturing facilities are located in New Brighton, Minnesota, Holliston, Massachusetts (USA), Reutlingen and March (Germany), and Barcelona (Spain).

Harvard Bioscience is recognized as a global leader in life science research tools. Its brands, including Harvard Apparatus, DSI, Buxco, Biochrom, BTX, and Heka, are known for their precision and reliability. The company's products are essential for pharmaceutical companies, academic institutions, and government laboratories, playing a critical role in drug discovery and basic research. No negative events impacting the brand reputation were found in the provided search results.

Harvard Bioscience has a significant number of institutional owners and shareholders. As of May 5, 2026, 61 institutional owners and shareholders have filed 13D/G or 13F forms, holding a total of 13,655,524 shares. Major institutional owners include Vanguard Group Inc, Acadian Asset Management Llc, and Meros Investment Management, LP. James W. Green owns the most individual shares. The ownership structure is composed of approximately 5.79% by Mutual Funds & ETFs, 49.84% by Other Institutional Investors, and 44.37% by Public Companies & Retail Investors.